Xbrane Biopharma publishes 2018 Annual Report

Annual

English

IR

Listing Regulation

News

Regulatory

Report

Xbrane Biopharma AB’s annual report for 2018 is now available at the company’s website, www.xbrane.com. The annual report is distributed to the shareholders and others that made such request. The annual report can also be ordered from Xbrane Biopharma on the following address:

Xbrane Biopharma AB
Banvaktsvägen 22
17148 Solna
Sweden

Or via e-mail: ir@xbrane.com

Contacts

Martin Åmark, CEO/IR
M: +46 (0) 763-093 777
E: martin.amark@xbrane.com

Susanna Helgesen, CFO
M: +46 (0) 708-278 636
E: susanna.helgesen@xbrane.com

About Us

Xbrane is a commercial phase Swedish biopharmaceutical company specialized in biosimilars. Xbrane has a patented protein production platform for development of biosimilars and world leading expertise in biosimilars. Xbrane’s headquarter is located in Solna outside of Stockholm and the company’s in-house research and development facilities are in Sweden and Italy. Xbrane is listed at Nasdaq First North since February 3rd, 2016 under the name XBRANE and Avanza Bank AB is Xbrane’s certified adviser (corp@avanza.se, +46 (0)8 409 421 20).
For more information see www.xbrane.com.

Attachments

Xbrane Publishes Annual Report For 2018